Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy

International Journal of Urology

Volumn 22, Issue 8, 2015, Pages 742-746

  Hinata, Nobuyuki ^a   Miyake, Hideaki ^a   Miyazaki, Akira ^a   Nishikawa, Masatomo ^a   Tei, Hiromoto ^a   Fujisawa, Masato ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Bladder cancer; Cystectomy; Karnofsky Performance Status; Survival

Indexed keywords

ADULT; ARTICLE; BLEEDING; CONTROLLED STUDY; DONOR SITE COMPLICATION; DORSAL ONLAY BUCCAL MUCOSAL GRAFT URETHROPLASTY; FLOW RATE; FOLLOW UP; GRAFT NECROSIS; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL PROSTATE SYMPTOM SCORE; LONG SEGMENT BULBAR URETHRAL STRICTURE; MAJOR CLINICAL STUDY; OPERATION DURATION; PATIENT SAFETY; PEROPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; THERAPY EFFECT; URETHRA STENOSIS; URETHROPLASTY; VENTRAL ONLAY BUCCAL MUCOSAL GRAFT URETHROPLASTY; WOUND HEMATOMA; WOUND INFECTION; AGED; BLADDER; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME; TUMOR RECURRENCE; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CARCINOMA, TRANSITIONAL CELL; CYSTECTOMY; FEMALE; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84937976526     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/iju.12804     Document Type: Article

References (19)

1. Chahal R, Sundaram SK, Iddenden R et al. A study of the morbidity, mortality and long-term survival following radical cystectomy and radical radiotherapy in the treatment of invasive bladder cancer in Yorkshire. Eur. Urol. 2003; 43: 246-57.
2. Shabsigh A, Korets R, Vora KC et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology. Eur. Urol. 2009; 55: 164-74.
3. Robbins JR, Gayar OH, Zaki M et al. Impact of age-adjusted Charlson comorbidity score on outcomes for patients with early-stage endometrial cancer. Gynecol. Oncol. 2013; 131: 593-7.
4. Kluth LA, Xylinas E, Kent M et al. Predictors of survival in patients with disease recurrence after radical nephroureterectomy. BJU Int. 2014; 113: 911-7.
5. Polley MY, Lamborn KR, Chang SM et al. Conditional probability of survival in patients with newly diagnosed glioblastoma. J. Clin. Oncol. 2011; 29: 4175-80.
6. Stein JP, Lieskovsky G, Cote R et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J. Clin. Oncol. 2001; 19: 666-75.
7. Quek ML, Stein JP, Nichols PW et al. Prognostic significance of lymphovascular invasion of bladder cancer treated with radical cystectomy. J. Urol. 2005; 174: 103-6.
8. May M, Herrmann E, Bolenz C et al. Lymph node density affects cancer-specific survival in patients with lymph node-positive urothelial bladder cancer following radical cystectomy. Eur. Urol. 2011; 59: 712-8.
9. Miller DC, Taub DA, Dunn RL et al. The impact of co-morbid disease on cancer control and survival following radical cystectomy. J. Urol. 2003; 169: 105-9.
10. Lee CT, Madii R, Daignault S et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol. 2006; 175: 1262-7.
11. Koppie TM, Serio AM, Vickers AJ et al. Age-adjusted Charlson comorbidity score is associated with treatment decisions and clinical outcomes for patients undergoing radical cystectomy for bladder cancer. Cancer 2008; 112: 2384-92.
12. Fairey A, Chetner M, Metcalfe J et al. Associations among age, comorbidity and clinical outcomes after radical cystectomy: results from the Alberta Urology Institute radical cystectomy database. J. Urol. 2008; 180: 128-34.
13. Weizer AZ, Joshi D, Daignault S et al. Performance status is a predictor of overall survival of elderly patients with muscle invasive bladder cancer. J. Urol. 2007; 177: 1287-93.
14. Evers PD, Logan JE, Sills V et al. Karnofsky performance status predicts overall survival, cancer-specific survival, and progression-free survival following radical cystectomy for urothelial carcinoma. World J. Urol. 2014; 32: 385-91.
15. Mayr R, May M, Martini T et al. Comorbidity and performance indices as predictors of cancer-independent mortality but not of cancer-specific mortality after radical cystectomy for urothelial carcinoma of the bladder. Eur. Urol. 2012; 62: 662-70.
16. Yates JW, Chalmer B, McKegney FP. Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 1980; 45: 2220-4.
17. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 2002; 20: 289-96.
18. Shaw AC, Goldstein DR, Montgomery RR. Age-dependent dysregulation of innate immunity. Nat. Rev. Immunol. 2013; 13: 875-87.
19. Masson-Lecomte A, Rava M, Real FX et al. Inflammatory biomarkers and bladder cancer prognosis: a systematic review. Eur. Urol. 2014; 66: 1078-91.